ArticleEClinicalMedicine2023

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial.

Ravi Savarirayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.